705 related articles for article (PubMed ID: 25782764)
1. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
[TBL] [Abstract][Full Text] [Related]
2. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.
Moskal JR; Burch R; Burgdorf JS; Kroes RA; Stanton PK; Disterhoft JF; Leander JD
Expert Opin Investig Drugs; 2014 Feb; 23(2):243-54. PubMed ID: 24251380
[TBL] [Abstract][Full Text] [Related]
3. NMDA antagonists under investigation for the treatment of major depressive disorder.
Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
5. GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine.
Liu RJ; Duman C; Kato T; Hare B; Lopresto D; Bang E; Burgdorf J; Moskal J; Taylor J; Aghajanian G; Duman RS
Neuropsychopharmacology; 2017 May; 42(6):1231-1242. PubMed ID: 27634355
[TBL] [Abstract][Full Text] [Related]
6. Scale-Up Synthesis and Identification of GLYX-13, a NMDAR Glycine-Site Partial Agonist for the Treatment of Major Depressive Disorder.
Li W; Liu J; Fan M; Li Z; Chen Y; Zhang G; Huang Z; Zhang L
Molecules; 2018 Apr; 23(5):. PubMed ID: 29695090
[TBL] [Abstract][Full Text] [Related]
7. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
8. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
Hillhouse TM; Porter JH
Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
[TBL] [Abstract][Full Text] [Related]
9. Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects.
Donello JE; Banerjee P; Li YX; Guo YX; Yoshitake T; Zhang XL; Miry O; Kehr J; Stanton PK; Gross AL; Burgdorf JS; Kroes RA; Moskal JR
Int J Neuropsychopharmacol; 2019 Mar; 22(3):247-259. PubMed ID: 30544218
[TBL] [Abstract][Full Text] [Related]
10. NMDA receptor partial agonist GLYX-13 alleviates chronic stress-induced depression-like behavior through enhancement of AMPA receptor function in the periaqueductal gray.
Yang PS; Peng HY; Lin TB; Hsieh MC; Lai CY; Lee AS; Wang HH; Ho YC
Neuropharmacology; 2020 Nov; 178():108269. PubMed ID: 32791085
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.
Zarate CA; Mathews D; Ibrahim L; Chaves JF; Marquardt C; Ukoh I; Jolkovsky L; Brutsche NE; Smith MA; Luckenbaugh DA
Biol Psychiatry; 2013 Aug; 74(4):257-64. PubMed ID: 23206319
[TBL] [Abstract][Full Text] [Related]
12. Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date.
Ragguett RM; Rong C; Kratiuk K; McIntyre RS
Expert Opin Investig Drugs; 2019 Feb; 28(2):113-119. PubMed ID: 30585524
[TBL] [Abstract][Full Text] [Related]
13. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.
Smith EG; Deligiannidis KM; Ulbricht CM; Landolin CS; Patel JK; Rothschild AJ
J Clin Psychiatry; 2013 Oct; 74(10):966-73. PubMed ID: 24229746
[TBL] [Abstract][Full Text] [Related]
15. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
17. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.
Burgdorf J; Zhang XL; Nicholson KL; Balster RL; Leander JD; Stanton PK; Gross AL; Kroes RA; Moskal JR
Neuropsychopharmacology; 2013 Apr; 38(5):729-42. PubMed ID: 23303054
[TBL] [Abstract][Full Text] [Related]
18. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.
Burgdorf J; Zhang XL; Weiss C; Gross A; Boikess SR; Kroes RA; Khan MA; Burch RM; Rex CS; Disterhoft JF; Stanton PK; Moskal JR
Neuroscience; 2015 Nov; 308():202-11. PubMed ID: 26343295
[TBL] [Abstract][Full Text] [Related]
19. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
Ghasemi M; Kazemi MH; Yoosefi A; Ghasemi A; Paragomi P; Amini H; Afzali MH
Psychiatry Res; 2014 Feb; 215(2):355-61. PubMed ID: 24374115
[TBL] [Abstract][Full Text] [Related]
20. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
